ImmunityBio, Inc. Insider Trading

IBRX

Last 12 months

Insiders sold $9.51M and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Jun 2023.

Net open-market

−$9.51M

0 buys · 12 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 3

executives and directors

Last open-market buy

Jun 2023

Jun 5, 2023

Get an email when IBRX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 5	Barry J. Simon Director	Sold10b5-1 plan	25,000	$10.75	269K	0.9%	Form 4
Oct 2	Cheryl Cohen Director	Sold10b5-1 plan	81,056	$10.50	851K	45%	Form 4
Jul 2	Cheryl Cohen Director	Sold10b5-1 plan	131,210	$9.50	$1.25M	51%	Form 4
Jul 1	Christobel Selecky Director	Sold10b5-1 plan	159,478	$9.02	$1.44M	100%	Form 4
Jun 29 – 30	Christobel Selecky Director	Sold10b5-1 plan 2 parts	96,722	$9.01 average	871K	100%	Form 4
Jun 24	Barry J. Simon Director	Sold10b5-1 plan	25,000	$7.88	197K	0.9%	Form 4
Jun 4	Barry J. Simon Director	Sold10b5-1 plan	23,033	$7.18	165K	0.8%	Form 4
Feb 24	Barry J. Simon Director	Sold10b5-1 plan	75,000	$12.01	901K	2.6%	Form 4
Feb 23	Christobel Selecky Director	Sold10b5-1 plan	25,000	$10.00	250K	100%	Form 4
Feb 20 – 23	Barry J. Simon Director	Sold10b5-1 plan 2 parts	175,000	$10.19 average	$1.78M	5.6%	Form 4
Jan 16 – 20	Christobel Selecky Director	Sold10b5-1 plan 2 parts	75,000	$5.84 average	438K	100%	Form 4
Jan 20	Barry J. Simon Director	Sold10b5-1 plan 2 parts	151,967	$7.20 average	$1.09M	4.7%	Form 4

Oct 510b5-1 plan
Barry J. Simon
Director · sold 25,000 at $10.75
269K
0.9% of stake
Oct 210b5-1 plan
Cheryl Cohen
Director · sold 81,056 at $10.50
851K
45% of stake
Jul 210b5-1 plan
Cheryl Cohen
Director · sold 131,210 at $9.50
$1.25M
51% of stake
Jul 110b5-1 plan
Christobel Selecky
Director · sold 159,478 at $9.02
$1.44M
100% of stake
Jun 29 – 3010b5-1 plan
Christobel Selecky
Director · sold 96,722 at avg $9.01
871K
100% of stake
Jun 2410b5-1 plan
Barry J. Simon
Director · sold 25,000 at $7.88
197K
0.9% of stake
Jun 410b5-1 plan
Barry J. Simon
Director · sold 23,033 at $7.18
165K
0.8% of stake
Feb 2410b5-1 plan
Barry J. Simon
Director · sold 75,000 at $12.01
901K
2.6% of stake
Feb 2310b5-1 plan
Christobel Selecky
Director · sold 25,000 at $10.00
250K
100% of stake
Feb 20 – 2310b5-1 plan
Barry J. Simon
Director · sold 175,000 at avg $10.19
$1.78M
5.6% of stake
Jan 16 – 2010b5-1 plan
Christobel Selecky
Director · sold 75,000 at avg $5.84
438K
100% of stake
Jan 2010b5-1 plan
Barry J. Simon
Director · sold 151,967 at avg $7.20
$1.09M
4.7% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch IBRX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with IBRX

CompareIntrinsic value

BEAMBeam Therapeutics Inc.

$27.79+5.55%40

DNAGinkgo Bioworks Holdings Inc.

$11.65+8.27%15

AGENAgenus Inc.

$6.97+4.50%46

IPSCCentury Therapeutics, Inc.

$1.67+9.87%40

STROSutro Biopharma, Inc.

$9.94+4.52%10

AUTLAutolus Therapeutics plc

$1.38-2.83%40

FDMT4D Molecular Therapeutics, Inc.

$12.28+2.76%40

RGNXRegenxbio Inc.

$7.71+1.05%40

Held by ETFs

IBRX is in 55 US ETFs. The largest of them, with IBRX's weight in each:

Spot a number that looks wrong? Check it in IBRX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing IBRX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.